Following our analysis of the options activities associated with Vertex Pharmaceuticals, we pivot to a closer look at the company's own performance. Where Is Vertex Pharmaceuticals Standing Right Now?

About Vertex Pharmaceuticals Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases.

The Motley Fool has positions in and recommends AbbVie, Abbott Laboratories, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a rare and progressive genetic disease, expanding the company’s presence ...

Comparing Vertex Pharmaceuticals's Short Interest Against Its Peers Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing.

The one-month return of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was 0.31%, and its shares lost 5.40% of their value over the last 52 weeks.

About Vertex Pharmaceuticals Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases.

Vertex Pharmaceuticals: 2025 TIME100 Most Influential CompaniesBoston and London biotech company Vertex Pharmaceuticals is on a roll. In the past year and a half, Vertex worked with CRISPR ...

U.S. | U.S. multinational company Abbott entered a partnership with Abu Dhabi's Department of Health to manufacture medicines in the United Arab Emirates capital as part of the country’s effort ...

On June 20, Vertex Pharmaceuticals announced the simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel ...

A Vertex Pharmaceuticals cell therapy for type 1 diabetes is enabling patients to produce insulin, eliminating the need for additional insulin therapy in the vast majority of participants in a key ...